Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin-aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women

Geriatrics and Gerontology International

Volumn 8, Issue 4, 2008, Pages 259-264

  Ichikawa, Akiko ^a   Sumino, Hiroyuki ^b   Ogawa, Tetsuya ^a   Ichikawa, Shuichi ^b   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Blood pressure; Bradykinin; Estrogen; Postmenopausal women; Renin angiotensin aldosterone system

Indexed keywords

BRADYKININ; ESTRADIOL; MEDROXYPROGESTERONE ACETATE;

AGED; ARTICLE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; BLOOD PRESSURE; BRADYKININ; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; RENIN-ANGIOTENSIN SYSTEM;

EID: 56649120259     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2008.00474.x     Document Type: Article

References (28)

1. Pang SC, Greendale GA, Cedars MI et al. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril 1993; 59: 76-82.
2. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33: 1190-1194.
3. Faguer de Moustier B, Conard J, Guyene TT etal. Comparative metabolic study of percutaneous versus oral micronized 17β-oestradiol in replacement therapy. Maturitas 1989; 11: 275-286.
4. Chetkowski RJ, Meldrum DR, Steingold KA etal. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620.
5. Schunkert H, Danser AHJ, Hense HW, Derkx FHM, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the rennin-angiotensin system in postmenopausal women. Circulation 1997; 95: 39-45.
6. Proudler AJ, Cooper A, Whitehead M, Stevenson JC. Effects of oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. Clin Endocr 2003; 58: 30-35.
7. De Lignieres B, Basdevant A, Thomas G et al. Biological effects of estradiol-17β in postmenopausal women: Oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-541.
8. Umeda M, Ichikawa S, Kanda T, Sumino H, Kobayashi I. Hormone replacement therapy increases plasma level of angiotensin II in postmenopausal hypertensive women. Am J Hypertens 2001; 14: 206-211.
9. Yamamoto T, Hiromoto J, Kikuchi Y, Oka M, Takatori O. Correlations among blood levels of renib-angiotensin-aldosterone, bradykinin, and catecholamines in healthy subjects. Clin Chim Acta 1989; 181: 197-200.
10. Sumino H, Ichikawa S, Sakamato H et al. Effects of conjugated equine estrogen and medroxyprogesterone acetate on lipoprotein(a) and other lipoproteins in Japanese postmenopausal women with and without dyslipidemia. Horm Res 2004; 62: 1-9.
11. Kasahara Y, Ashihara Y. Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 1981; 27: 1922-1925.
12. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
13. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002; 105: 213-217.
14. Berliner JA, Navab M, Fogelman AM et al. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
15. Oger E, Alhenc-Gelas M, Plu-Bureau G et al. Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users. Thromb Res 2001; 101: 35-43.
16. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-1292.
17. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155: 701-709.
18. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
19. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701-1712.
20. Pradhan AD, Manson JE, Rossouw JE et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980-987.
21. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733.
22. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA 1995; 273: 199-208.
23. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.
24. Lacut K, Oger E, Le Gal G etal. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003; 90: 124-131.
25. Sumino H, Ichikawa S, Ohyama Y et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol 2005; 96: 148-153.
26. Sumino H, Ichikawa S, Kasama S et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005; 28: 579-584.
27. Sumino H, Ichikawa S, Kasama S et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006; 189: 436-442.
28. Vehkavaara S, Silveria A, Hakala-Ala-Pietila T et al. Effects of oral and transdermal estrogen replacement therapy on makers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-625.